Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2006

01.12.2006 | Original Article

Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel

verfasst von: Kohji Takara, Yukihisa Obata, Eri Yoshikawa, Noriaki Kitada, Toshiyuki Sakaeda, Noriaki Ohnishi, Teruyoshi Yokoyama

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective: To achieve a reversal of multidrug resistance (MDR) in cancer chemotherapy, it is crucial to clarify the characteristics of MDR cells generated by various types of chemotherapeutic agents and to find novel targets. Methods: Cisplatin- and paclitaxel-resistant HeLa sublines (HeLa/CDDP and HeLa/TXL, respectively) were established by continuous exposure and their cellular changes were examined based on growth inhibition assays, the transport activity of P-glycoprotein/MDR1, and a RT-PCR analysis of MDR-related factors. Results: HeLa/CDDP cells showed cross-resistance to platinum derivatives, whereas HeLa/TXL cells were resistant to a variety of MDR1 substrates. Transport activity of MDR1 was reduced in HeLa/CDDP cells and the expression of MDR1 was significantly accelerated in HeLa/TXL cells, compared with HeLa cells. In addition, the expression levels of MDR-related transporters (MRP1–5 or BCRP), βtubulin which is a target for taxanes, and apoptosis-regulated factors were comparable among the three cell lines. On the other hand, the mRNA levels of γ-glutamyl transferase, but not γ-glutamyl cysteine synthetase, were higher in HeLa/CDDP cells than in HeLa and HeLa/TXL cells. Conclusions: HeLa/CDDP cells showed decreased activity and expression of MDR1 and overexpression of \( \ifmmode\expandafter\tilde\else\expandafter\sim \fi{\gamma }{\text{-GT}} \) but not \( \ifmmode\expandafter\tilde\else\expandafter\sim \fi{\gamma }{\text{-GCS,}} \) whereas the activity of MDR1 in HeLa/TXL cells was significantly enhanced. Thus, the molecular changes to HeLa cells caused by continuous exposure to cisplatin or paclitaxel were in part clarified, and therefore an understanding of the cellular changes induced by chemotherapeutic agents will be necessary to establish a strategy for reversing MDR.
Literatur
1.
Zurück zum Zitat Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279PubMedCrossRef Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279PubMedCrossRef
2.
Zurück zum Zitat Wang G, Reed E, Li QQ (2004) Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12(5):955–965PubMed Wang G, Reed E, Li QQ (2004) Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12(5):955–965PubMed
3.
Zurück zum Zitat Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5(1):15–27PubMedCrossRef Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5(1):15–27PubMedCrossRef
4.
Zurück zum Zitat Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer. Curr Pharm Des 12(3):273–286PubMedCrossRef Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer. Curr Pharm Des 12(3):273–286PubMedCrossRef
5.
Zurück zum Zitat Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292PubMedCrossRef Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292PubMedCrossRef
6.
Zurück zum Zitat Takara K, Sakaeda T, Okumura K (2004) Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. Anticancer Drugs 15(4):303–309PubMedCrossRef Takara K, Sakaeda T, Okumura K (2004) Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. Anticancer Drugs 15(4):303–309PubMedCrossRef
7.
Zurück zum Zitat Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25(6):771–778PubMedCrossRef Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25(6):771–778PubMedCrossRef
8.
Zurück zum Zitat Abbott BL (2003) ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 21(3):115–130PubMedCrossRef Abbott BL (2003) ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 21(3):115–130PubMedCrossRef
9.
Zurück zum Zitat Hoffmann U, Kroemer HK (2004) The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36(3–4):669–701PubMedCrossRef Hoffmann U, Kroemer HK (2004) The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36(3–4):669–701PubMedCrossRef
10.
Zurück zum Zitat Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8(5):411–424PubMedCrossRef Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8(5):411–424PubMedCrossRef
11.
Zurück zum Zitat Takara K, Horibe S, Obata Y, Yoshikawa E, Ohnishi N, Yokoyama T (2005) Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull 28(1):138–142PubMedCrossRef Takara K, Horibe S, Obata Y, Yoshikawa E, Ohnishi N, Yokoyama T (2005) Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull 28(1):138–142PubMedCrossRef
12.
Zurück zum Zitat Takara K, Tsujimoto M, Kokufu M, Ohnishi N, Yokoyama T (2003) Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol Pharm Bull 26(2):205–209PubMedCrossRef Takara K, Tsujimoto M, Kokufu M, Ohnishi N, Yokoyama T (2003) Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol Pharm Bull 26(2):205–209PubMedCrossRef
13.
Zurück zum Zitat Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2002) Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 292(1):190–194PubMedCrossRef Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2002) Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 292(1):190–194PubMedCrossRef
14.
Zurück zum Zitat Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. J Pharm Pharmacol 55(5):675–681PubMedCrossRef Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. J Pharm Pharmacol 55(5):675–681PubMedCrossRef
15.
Zurück zum Zitat Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMed Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMed
16.
Zurück zum Zitat Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306(1):116–120PubMedCrossRef Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306(1):116–120PubMedCrossRef
17.
Zurück zum Zitat Carles G, Braguer D, Dumontet C, Bourgarel V, Goncalves A, Sarrazin M, Rognoni JB, Briand C (1999) Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 80(8):1162–1168PubMedCrossRef Carles G, Braguer D, Dumontet C, Bourgarel V, Goncalves A, Sarrazin M, Rognoni JB, Briand C (1999) Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 80(8):1162–1168PubMedCrossRef
18.
Zurück zum Zitat Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM (2001) Differential regulation of γ-glutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta 1568(1):67–73PubMed Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM (2001) Differential regulation of γ-glutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta 1568(1):67–73PubMed
19.
Zurück zum Zitat Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92(4):452–458PubMed Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92(4):452–458PubMed
20.
Zurück zum Zitat Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282–1293PubMedCrossRef Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282–1293PubMedCrossRef
21.
Zurück zum Zitat Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57(16):3537–3547PubMed Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57(16):3537–3547PubMed
22.
Zurück zum Zitat Liu B, Staren ED, Iwamura T, Appert HE, Howard JM (2001) Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99(2):179–186PubMedCrossRef Liu B, Staren ED, Iwamura T, Appert HE, Howard JM (2001) Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99(2):179–186PubMedCrossRef
23.
Zurück zum Zitat Myhrstad MC, Carlsen H, Nordstrom O, Blomhoff R, Moskaug JO (2002) Flavonoids increase the intracellular glutathione level by transactivation of the γ-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med 32(5):386–393PubMedCrossRef Myhrstad MC, Carlsen H, Nordstrom O, Blomhoff R, Moskaug JO (2002) Flavonoids increase the intracellular glutathione level by transactivation of the γ-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med 32(5):386–393PubMedCrossRef
24.
Zurück zum Zitat Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S (2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22(1A):121–128PubMed Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S (2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22(1A):121–128PubMed
25.
Zurück zum Zitat Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRef Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRef
26.
Zurück zum Zitat Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685PubMedCrossRef Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685PubMedCrossRef
27.
Zurück zum Zitat Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7(5):584–590PubMedCrossRef Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7(5):584–590PubMedCrossRef
28.
Zurück zum Zitat Li Q, Sai Y, Kato Y, Tamai I, Tsuji A (2003) Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res 20(8):1119–1124PubMedCrossRef Li Q, Sai Y, Kato Y, Tamai I, Tsuji A (2003) Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res 20(8):1119–1124PubMedCrossRef
29.
Zurück zum Zitat Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070–3074PubMedCrossRef Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070–3074PubMedCrossRef
30.
Zurück zum Zitat Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J (1997) Enhanced expression of γ-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157(3):1054–1058PubMedCrossRef Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J (1997) Enhanced expression of γ-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157(3):1054–1058PubMedCrossRef
31.
Zurück zum Zitat Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M, Saijo N (1995) γ-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216(1):258–264PubMedCrossRef Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M, Saijo N (1995) γ-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216(1):258–264PubMedCrossRef
32.
Zurück zum Zitat Tipnis SR, Blake DG, Shepherd AG, McLellan LI (1999) Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance. Biochem J 337(3):559–566PubMedCrossRef Tipnis SR, Blake DG, Shepherd AG, McLellan LI (1999) Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance. Biochem J 337(3):559–566PubMedCrossRef
33.
Zurück zum Zitat El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105(1):5–14PubMedCrossRef El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105(1):5–14PubMedCrossRef
34.
Zurück zum Zitat Daubeuf S, Balin D, Leroy P, Visvikis A (2003) Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol 66(4):595–604PubMedCrossRef Daubeuf S, Balin D, Leroy P, Visvikis A (2003) Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol 66(4):595–604PubMedCrossRef
35.
Zurück zum Zitat Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77(4):562–566PubMed Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77(4):562–566PubMed
36.
Zurück zum Zitat Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93(3):1075–1085PubMed Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93(3):1075–1085PubMed
37.
Zurück zum Zitat Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A, Yagami T, Kobayashi H, Nagata S, Okamura N, Yoshikawa T, Shirakawa T, Gotoh A, Matsuo M, Okumura K (2002) MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 19(9):1323–1329PubMedCrossRef Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A, Yagami T, Kobayashi H, Nagata S, Okamura N, Yoshikawa T, Shirakawa T, Gotoh A, Matsuo M, Okumura K (2002) MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 19(9):1323–1329PubMedCrossRef
38.
Zurück zum Zitat Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95(12):7024–7029PubMedCrossRef Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95(12):7024–7029PubMedCrossRef
Metadaten
Titel
Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel
verfasst von
Kohji Takara
Yukihisa Obata
Eri Yoshikawa
Noriaki Kitada
Toshiyuki Sakaeda
Noriaki Ohnishi
Teruyoshi Yokoyama
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0226-5

Weitere Artikel der Ausgabe 6/2006

Cancer Chemotherapy and Pharmacology 6/2006 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.